KLRK1 and neoplasm: MDSCs induce NK cell inactivation, decrease the expression of NK-cell-activating receptors (e.g., NKG2D), interfere with NK cell cytotoxicity, and simultaneously reduce IFN-γ production to impair anti-tumor immunity [46,47].